TITLE:
Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)

CONDITION:
Prostate Cancer

INTERVENTION:
rofecoxib

SUMMARY:

      To determine the efficacy and safety of an investigational compound (MK0966) for the
      prevention of prostate cancer.
    

DETAILED DESCRIPTION:

      The duration of treatment is 6 years.
    

ELIGIBILITY:
Gender: Male
Age: 50 Years to 75 Years
Criteria:

        Regular PSA testing and study biopsies required.
      
